Posterior Segment Eye Disorders Market Analysis & Forecast: 2026-2033
The Posterior Segment Eye Disorders Market size is anticipated to grow at a CAGR of 5% with USD 35.7 Bn in 2026 and is expected to reach USD 50.2 Bn in 2033. The growth of the market is being driven by rising diabetic retinopathy burden, increasing prevalence of age-related macular degeneration, wider use of anti-VEGF therapies, and rapid adoption of retinal imaging and AI-assisted screening. According to the World Health Organization, at least 2.2 Bn people across the glove have near or distance vision impairment, and at least 1 Bn cases could have been prevented or remain unaddressed. This is strengthening the demand for intravitreal therapies, retinal imaging platforms, sustained-delivery implants, and specialist retinal care services across both hospitals as well as ophthalmology clinics.
Drugs segment is projected to account for the largest Posterior Segment Eye Disorders Market share of 68.4% in 2026. The segment’s growth is owing to a combination of high clinical reliance on pharmacologic therapies for retinal diseases such as diabetic retinopathy and age‑related macular degeneration, and sustained regulatory activity in ocular drug approvals and clinical development.
The FDA expanded the label for ANIP’s ILUVIEN (fluocinolone acetonide intravitreal implant) to include chronic non‑infectious uveitis affecting the posterior segment, broadening therapeutic access in this segment.
In March 2026, EyePoint, Inc. dosed the first patients in the pivotal Phase 3 COMO and CAPRI trials of DURAVYU (vorolanib intravitreal insert) for diabetic macular edema (DME), representing a significant advancement in sustained intravitreal drug delivery for posterior segment diseases.
To learn more about this report, Request Free Sample
Based on application, the macular degeneration segment is poised to dominate the market and accounts for a considerable 39.8% share in 2026. The segment’s growth is owing to the rising prevalence of age-related macular degeneration (AMD), which, according to the National Institutes of Health (NIH), is expected to affect over 160 million individuals globally by 2045.
The growing adoption of advanced diagnostic techniques is also supporting this trend. According to the NIH and CDC surveillance data, around more than 30 million optical coherence tomography (OCT) procedures are conducted annually worldwide to detect AMD, diabetic retinopathy, and other posterior segment disorders.
In March 2025, the Food and Drug Administration approved revakinagene taroretcel-lwey (Encelto). It is the first cell-based gene therapy for adults with idiopathic macular telangiectasia type 2. The therapy delivers continuous ciliary neurotrophic factor to the retina to slow the progressive vision loss.
The posterior segment eye disorders market in the U.S. is witnessing strong innovation in sustained drug delivery, long-acting biologics, and AI-enabled retinal screening. These innovations are important because posterior segment disorders require frequent monitoring and repeated intravitreal injections, thereby creating treatment burden for patients, caregivers, and retina specialists. The long-acting therapies and refillable implants are being developed to reduce injection frequency, improve adherence, and maintain vision outcomes over a longer period. This is particularly relevant for diabetic macular edema, diabetic retinopathy, wet AMD, and retinal vein occlusion, where chronic treatment is common.
In February 2025, Genentech received U.S. FDA approval for Susvimo for the treatment of diabetic macular edema. The company stated that Susvimo is the first FDA-approved treatment shown to maintain vision in people with DME with fewer treatments than standard-of-care eye injections. In May 2025, Genentech also announced FDA approval of Susvimo for diabetic retinopathy, making it a continuous delivery option with one refill every nine months for previously anti-VEGF-responsive patients. These developments are expected to strengthen the adoption of sustained-delivery platforms across both retina specialists as well as ophthalmology centers.
The long-acting anti-VEGF formulations and port delivery systems is one of a major breakthrough in the posterior segment eye disorders market. Anti-VEGF therapies remain central to the treatment of wet AMD, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion because they inhibit abnormal retinal blood vessel growth and vascular leakage. Long-acting biologics and refillable delivery platforms are designed to extend dosing intervals while maintaining vision outcomes.
In April 2026, Regeneron announced that Eylea HD 8 mg received the FDA approval as the first injectable anti-VEGF with dosing intervals up to five months for wet AMD and diabetic macular edema. This is important because extended dosing may reduce the frequency of retina clinic visits while preserving treatment efficacy for chronic posterior segment diseases.
In addition, Roche reported that Vabysmo is approved in more than 100 countries for neovascular AMD and diabetic macular edema, and in more than 60 countries for macular edema following retinal vein occlusion. The firm also stated that more than eight million Vabysmo doses had been distributed globally since its initial U.S. approval. This reflects strong global uptake of bispecific retinal biologics targeting VEGF-A and Ang-2 pathways. Such innovations are expected to speed up the Posterior Segment Eye Disorders Market growth during the forecast period.
|
Current Event |
Description and its Impact |
|
FDA Draft Framework for Accelerating Individualized Ophthalmic Therapies (2026) |
|
|
EU Pharmaceutical Legislation Revision for Rare Ophthalmic Diseases (2026) |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
North America is set to account for the leading position in the Posterior Segment Eye Disorders Market. The region occupies a substantial 39.4% share in 2026. The growth is mainly driven by the high disease diagnosis rates, established retina-specialist networks, strong reimbursement for intravitreal therapy, and rapid uptake of FDA-approved biologics and imaging technologies.
According to the CDC, more than 9.6 million people in the U.S. are living with diabetic retinopathy. According to the National Eye Institute, around 11 million people in the U.S. have age-related macular degeneration.
The region also benefits from rapid regulatory approvals. In April 2026, Genentech received FDA approval for an updated Vabysmo label extending treatment for macular edema following retinal vein occlusion beyond six months. Genentech stated that RVO affects over one million Americans, highlighting a sizable chronic-treatment population. This strengthens North America’s role as a key launch and adoption market for posterior segment therapies.
The Asia Pacific region is poised to be as the fastest-growing region through 2026-2033. The region’s growth is owing to the large diabetes populations, aging demographics, increasing ophthalmology infrastructure, and rising public-health focus on vision care.
According to WHO South-East Asia, the number of people with diabetes in seven countries of the region was expected to increase from 87.6 million in 2019 to 115.1 million in 2030, supporting higher diabetic retinopathy screening and treatment demand.
In India, a national survey-based study reported diabetic retinopathy prevalence of 16.9% among persons with diabetes and sight-threatening diabetic retinopathy prevalence of 3.6%. These figures indicate significant unmet need for retinal screening, imaging, and treatment expansion.
In October 2025, Everest Medicines acquired exclusive rights to develop, manufacture, and commercialize VIS-101 across Greater China, Singapore, South Korea, and Southeast Asia. The VEGF-A/ANG-2-targeting biologic treats wet AMD, diabetic macular edema, and retinal vein occlusion, with Phase 3 readiness expected in 2026.
The United States Posterior Segment Eye Disorders Market has seen robust growth. The growth is owing to the early adoption of retinal biologics, high treatment availability, and strong regulatory activity. According to Genentech, more than 10 million people in the U.S. are living with vision-threatening diabetic retinopathy. This supports the demand for OCT imaging, anti-VEGF injections, steroid implants, and sustained drug delivery.
In July 2025, Alcon, Inc. announced plans to acquire LumiThera and its photobiomodulation technology for early/intermediate dry AMD. This acquisition is expanding the treatment options for retinal disease and strengthening its posterior segment therapy portfolio.
China is growing at a rapid pace owing to a large diabetic population, expanding ophthalmology infrastructure, and policy focus on eye health. A national Chinese study in Nature Communications reported diabetic retinopathy prevalence of 16.3% among people with diabetes, while vision-threatening diabetic retinopathy prevalence was 3.2%.
China is also strengthening vision-care programs. In October 2025, WHO reported that China launched the WHO SPECS 2030 Initiative and a national action plan to improve access to vision care. Although the initiative focuses strongly on refractive error, it reflects broader policy attention toward eye-care access and screening infrastructure. This is expected to indirectly support retinal disease detection through improved public awareness and organized eye-care delivery.
Some of the major key players in Posterior Segment Eye Disorders industry are Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche AG, AbbVie Inc (Allergan), Alcon Inc., Bausch Health Companies Inc., Aerie Pharmaceuticals, Santen Pharmaceutical Co. Ltd., Second Sight Medical Products Inc., Rainbow Medical Ltd (Nano Retina), and Regeneron Pharmaceuticals Inc., among others.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 35.7 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5% | 2033 Value Projection: | USD 50.2 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche AG, AbbVie Inc (Allergan), Alcon Inc., Bausch Health Companies Inc., Aerie Pharmaceuticals, Santen Pharmaceutical Co. Ltd., Second Sight Medical Products Inc., Rainbow Medical Ltd (Nano Retina), and Regeneron Pharmaceuticals Inc., among others. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
